Maximum quantity allowed is 999
Bitte wählen Sie die Menge aus.
We offer a large selection of reagents that can be used for the preparation of carbohydrate compound combinations and carbohydrate-protein combinations in addition to tools for the evaluation of oligosaccharides conjugated to human serum albumin (HSA).
HSA-Oligosaccharide Conjugates
We offer carbohydrate-conjugated human serum albumin (HSA) which is manufactured using high-purity synthesized carbohydrates. Several sugar-conjugates are available, and it is also possible to manufacture the sugar-conjugates according to customer specifications. For more details on the products and contracts, please contact us.
HSA-Gb3 (Product No. H1718), a useful tool for the discovery and characterization of globotriose (Gb3)-binding substances
Anti-Gb3 monoclonal antibody satisfactorily reacts with HSA-Gb3, but not with BSA conjugated to Gb3 by reductive amination. Reductive amination eliminates the epitope by opening the pyranose ring at the reducing end. We offer closed-ring glycoconjugates via PEG linkers as useful tools for discovery and characterization of carbohydrate-binding substances.
Products
Examples of Sugar Conjugates
Carbohydrates for Conjugation
Aminoethyl Glycosides, Aminopropyl Glycosides
Glycosyl Azides
Biotin-Glyco-conjugates
- F1021
- Fucα(1-6)GlcNAc-β-propylamido-biotin
- G0511
- Galβ(1-3)GlcNAcβ(1-3)Galβ(1-3)GlcNAc-β-PEG3-biotin
- G0512
- Galβ(1-3)GlcNAc[6S]β(1-3)Galβ(1-3)GlcNAc[6S]-β-PEG3-biotin
- G0513
- Galβ(1-3)GlcNAcβ(1-3)Galβ(1-4)GlcNAc-β-PEG3-biotin
- G0514
- Galβ(1-3)GlcNAc[6S]β(1-3)Galβ(1-4)GlcNAc[6S]-β-PEG3-biotin
- G0515
- Galβ(1-4)GlcNAcβ(1-3)Galβ(1-4)GlcNAc-β-PEG3-biotin
- G0516
- L2-L2-β-PEG3-biotin
- G0517
- L4-L4-β-PEG3-biotin
- G0297
- N-GlcNAc-Biotin
- H1487
- HNK-1 Biotin
- M2985
- M3-biotin
- M2986
- M3(Fuc6)-biotin
Applications of Sugar Conjugates
Immunotherapy (cell transfer therapy)
Therapeutic antibodies and cancer vaccines are based on cancer cell recognition by immune cells, eventually collaborating to destroy cancer cells. In cell transfer therapy, immune cells are removed from the patient’s body, engineered to attack cancer cells, and then returned to the body. Research into the application of carbohydrate reagents is also increasing.
Cytotoxic T Lymphocyte (CTL)
Cellular immune responses resulting from cytotoxic T cells, also known as cytotoxic T lymphocytes (CTL), generate effector cells and attack cancer cells. Stimulating lymphocytes with “cancer antigens”, which only exist on cancer cells, will increase the number of CTLs specifically targeting cancer cells. Therapeutic response is also affected if specific CTLs are increased or administered. Currently, there is a global research effort to develop methods to increase specific cell types.
Dendritic cell therapy
Dendritic cells are branched antigen-presenting cells known for their “tree-like” shapes, which have the ability to present antigens to lymphocytes. Cytotoxic T lymphocytes can be induced if cancer antigens are presented to major histocompatibility complex (MHC) molecules on cell surfaces using the antigen-presenting ability of these cells, and this is a promising approach to cancer treatment.
α-Galactosyl Ceramide (α-GalCer)
α-Galactosyl Ceramide (α-GalCer) (Product No. G0509) is an artificial glycolipid which has been developed based on the sphingolipid extracted from the sea sponge, Agelas mauritianus. Work conducted by Prof. Taniguchi demonstrated that α-GalCer forms a complex with the CD1d antigen present on cell surfaces. This complexing results in strong NKT (Natural Killer T) cell activation causing high levels of cytokine production. The NKT cells bare features of both of NK cells and T cells.
Since α-GalCer is related to immune functions, it is used in disease research on cancer, atopic dermatitis and asthma and also is used as an adjuvant for experiment and research. Moreover, a synthetic intermediate of α-GalCer is required in synthetic research of analogs containing different functional groups such as unsaturation and aromatic groups on the ceramide moiety which can increase biological activity of α-GalCer.
We can provide large amount of α-GalCer and its intermediates synthesized in our facilities. Additionally, we can offer highly pure α-GalCer for use as a standard and other applications.